糖皮质激素治疗与COVID-19及SARS患者死亡率关联的比较:系统评价与Meta分析
该系统评价与Meta分析检索2002年至2020年10月7日多个数据库,纳入10项试验和71项观察性研究、共45935例患者,比较糖皮质激素治疗组与对照组死亡风险。结果显示,糖皮质激素治疗与COVID-19全因死亡率降低相关(RR 0.88,95%CI 0.82-0.94,I²=26%),也与SARS全因死亡率降低相关(RR 0.48,95%CI 0.29-0.79,I²=10%),基于高质量证据;COVID-19复合结局死亡率亦降低(RR 0.89,95%CI 0.82-0.98,I²=0%)。亚组分析提示两病在性别、年龄、剂量和用药时机上疗效存在差异。
要点
- 糖皮质激素治疗与COVID-19全因死亡率降低相关(RR 0.88,95%CI 0.82-0.94,I²=26%),证据质量高。
- 糖皮质激素治疗与SARS全因死亡率降低相关(RR 0.48,95%CI 0.29-0.79,I²=10%),证据质量高。
- COVID-19亚组中,合并严重ARDS、危重型、高龄、男性、非早期用药、使用地塞米松或甲泼尼龙、炎症状态升高者死亡率显著降低,轻型ARDS、年轻、女性者未观察到此关联。
- SARS亚组中,使用中高剂量糖皮质激素、重型或危重型、早期用药、使用甲泼尼龙或泼尼松龙者死亡率降低。
- 两病在性别和年龄特异性效应、最佳剂量及用药时机上存在不同疗效。
适用人群与场景
- COVID-19患者与SARS患者,涵盖不同严重程度(轻型、重型、危重型)及不同亚组(性别、年龄、炎症状态)。
处置流程与药物剂量
- COVID-19亚组中,使用低剂量或冲击剂量糖皮质激素、地塞米松或甲泼尼龙、非早期给药者,全因死亡率显著降低。
- SARS亚组中,使用中高剂量糖皮质激素、甲泼尼龙或泼尼松龙、早期给药者,死亡率降低。
研究设计与关键结果
- 系统评价与Meta分析,纳入10项试验和71项观察性研究,共45,935例患者,检索Medline、Embase、EBSCO、ScienceDirect、Web of Science、Cochrane Library、ClinicalTrials.gov、International Clinical Trials Registry Platform,检索时间2002年至2020年10月7日。
- 糖皮质激素治疗与COVID-19全因死亡率降低相关(RR 0.88,95%CI 0.82-0.94,I²=26%),基于高质量证据。
- 糖皮质激素治疗与SARS全因死亡率降低相关(RR 0.48,95%CI 0.29-0.79,I²=10%),基于高质量证据。
- 糖皮质激素治疗与COVID-19全因死亡率-复合结局降低相关(RR 0.89,95%CI 0.82-0.98,I²=0%)。
- COVID-19亚组:合并严重ARDS者全因死亡率显著降低,轻型ARDS者未观察到显著降低;使用低剂量或冲击剂量糖皮质激素者死亡率显著降低;危重型(非仅重型)者死亡率显著降低;危重型且高龄(非年轻)者死亡率显著降低;危重型且男性(非女性)者死亡率显著降低;非早期用药者死亡率显著降低;使用地塞米松或甲泼尼龙者死亡率显著降低;炎症状态升高者死亡率显著降低。
- SARS亚组:使用中高剂量糖皮质激素者死亡率降低;重型或危重型者死亡率降低;早期用药者死亡率降低;使用甲泼尼龙或泼尼松龙者死亡率降低。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析;原文报告基于高质量证据。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于COVID-19危重型患者,尤其是高龄、男性、合并严重ARDS、炎症状态升高者,糖皮质激素治疗(地塞米松或甲泼尼龙,低剂量或冲击剂量)与死亡率降低相关。
- 对于SARS重型或危重型患者,早期使用中高剂量糖皮质激素(甲泼尼龙或泼尼松龙)与死亡率降低相关。
- 两病在性别、年龄、最佳剂量和用药时机上疗效存在差异,临床决策时需考虑这些亚组特征。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The response to glucocorticoids treatment may be different between coronavirus disease 2019 (Covid-19) and severe acute respiratory syndrome (SARS).
METHODS: In this systematic review and meta-analysis, we searched studies on Medline, Embase, EBSCO, ScienceDirect, Web of Science, Cochrane Library, ClinicalTrials.gov, International Clinical Trials Registry Platform from 2002 to October 7, 2020. We used fixed-effects and random-effects models to compute the risk ratio of death in the group receiving glucocorticoids treatment and the control group for COVID-19 and SARS, respectively.
RESULTS: Ten trials and 71 observational studies, with a total of 45,935 patients, were identified. Glucocorticoids treatment was associated with decreased all-cause mortality both in COVID-19 (risk ratio, 0.88; 95% confidence interval, 0.82-0.94; I2 = 26%) and SARS (0.48; 0.29-0.79; 10%), based on high-quality evidence, as well as decreased all-cause mortality-including composite outcome of COVID-19 (0.89; 0.82-0.98; 0%). In subgroup analyses, all-cause mortality was significantly lower among COVID-19 patients being accompanied by severe ARDS but not mild ARDS, taking low-dose or pulse glucocorticoids, being critically severe but not only severe, being of critical severity and old but not young, being of critical severity and men but not women, non-early taking glucocorticoids, taking dexamethasone or methylprednisolone, and with the increased inflammatory state; but for SARS, lower mortality was observed among those who were taking medium-high dose glucocorticoids, being severe or critically severe, early taking glucocorticoids, and taking methylprednisolone or prednisolone.
CONCLUSIONS: Glucocorticoids treatment reduced mortality in COVID-19 and SARS patients of critical severity; however, different curative effects existed between the two diseases among subpopulations, mainly regarding sex- and age-specific effects, optimal doses, and use timing of glucocorticoids.
参考来源
- Li J, Liao X, Zhou Y, et al. Comparison of Associations Between Glucocorticoids Treatment and Mortality in COVID-19 Patients and SARS Patients: A Systematic Review and Meta-Analysis. Shock. 2021. PMID: 33555845. doi:10.1097/SHK.0000000000001738
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。